# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Liliʻuokalani (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET024-SYN
- Date: 2026-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kealani Morrison-Takeda, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review after the stroke. **S**

## History of present illness

Liliʻuokalani returns three months after the stroke. She has had no new neurological symptoms. The nosebleed four weeks ago has not recurred since she began using a nasal gel and a humidifier. She takes apixaban twice daily and has missed no doses. She plays the piano and has resumed composing, though she tires at the end of a long day. Her home blood pressure averages 124/72. She had a video review with Dr. Abernethy-Sato last week, who agreed with apixaban and the current plan. She has had no falls. She sleeps well and does not snore, by her household's account. **S**

| Element | Detail |
|---|---|
| Function | Composing and playing daily; modified Rankin Scale 1 |
| Mood | PHQ-9 4 |
| Home blood pressure | Average 124/72 mmHg |
| Anticoagulant | No missed doses; one minor nosebleed four weeks ago |
| Sleep | STOP-Bang 2 (age and treated blood pressure) |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No weakness, numbness, speech, vision or balance problem |
| Hematologic | Negative | No further nosebleeds; no black stools or blood in the urine |
| Psychiatric | Negative | Mood steady; sleeping well |
| Constitutional | Positive | Tired at the end of long days |

4 systems reviewed. **S**

## Current medications

- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Losartan 25 mg oral tablet, one tablet daily **S**
- Apixaban 5 mg oral tablet, one tablet twice daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/74 mmHg; pulse 70 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 57.6 kg; BMI 22.5 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 0.84 mg/dL; eGFR (CKD-EPI 2021): 71 mL/min/1.73 m²; Glucose: 95 mg/dL; Hemoglobin: 12.6 g/dL; Modified Rankin Scale: 1; PHQ-9: 4. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.84 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 73 mL/min/1.73 m² at baseline, 71 mL/min/1.73 m² at this visit **S**
- Glucose: 98 mg/dL at baseline, 95 mg/dL at this visit **S**
- Hemoglobin: 12.8 g/dL at baseline, 12.6 g/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/74, pulse 70 and regular; weight 57.6 kg |
| Neurological | Normal speech, strength, fine finger movements and gait |
| Nose | Left anterior septum healed; no crusting |
| Musculoskeletal | Timed Up and Go 11 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Minor ischemic stroke** (I63.412). No recurrence at three months; modified Rankin Scale 1; no rehabilitation needed. PHQ-9 4: no depression. **S**
   - Continue apixaban, atorvastatin and losartan.
   - MoCA again at the five-month review.
2. **Paroxysmal atrial fibrillation on apixaban** (I48.0). Regular rhythm today; no bleeding since the nosebleed; hemoglobin 12.6 g/dL and creatinine 0.84 mg/dL. **S**
   - No change; blood count and kidney function at the five-month review.
3. **Hypertension** (I10). At goal: 126/74 in the clinic, 124/72 at home; potassium 4.4 mmol/L. **S**
   - Continue losartan 25 mg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic and at home (target below 130/80 mmHg) and weight | Every visit | Completed today | 126/74 mmHg; home average 124/72; 57.6 kg |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | About two weeks after starting, then every six months | Completed today | Potassium 4.4 mmol/L, creatinine 0.84 mg/dL (eGFR 71) |
| Medication safety | Antithrombotic therapy and adherence | Every visit | Completed today | Apixaban twice daily, no missed doses; one minor nosebleed, managed without stopping it |
| Laboratory | Anticoagulant safety: blood count, kidney function (creatinine clearance) and liver tests | Before starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her) | Completed today | Hemoglobin 12.6 g/dL; creatinine 0.84 mg/dL |
| Survey | Neurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptoms | Modified Rankin Scale at 90 days | Completed today | Modified Rankin Scale 1; no new symptoms |
| Survey | Depression screen (PHQ-2, PHQ-9) | At the first post-stroke visit, then at least yearly | Completed today | PHQ-9 4; item 9 scored 0 |
| Survey | Cognitive screen (MoCA) | After the event, again within the first year, then periodically | Up to date | MoCA 26 after the stroke; repeat at the five-month review |
| Laboratory | Lipid panel (LDL goal below 70 mg/dL) | Four to twelve weeks after starting a statin, then every three to twelve months | Up to date | LDL 64 mg/dL at five weeks; repeat at five months |
| Examination | Falls risk | Every visit | Completed today | No falls; Timed Up and Go 11 seconds |
| Survey | Obstructive sleep apnea screen (STOP-Bang) | After a stroke | Completed today | STOP-Bang 2: low risk; no sleep study needed |
| Referral | Rehabilitation (physical, occupational and speech therapy) | At discharge and during recovery | Not indicated | No residual deficit; modified Rankin Scale 1 |
| Self-management | Tobacco, alcohol and physical activity | Every visit | Completed today | Never smoker; alcohol rarely; walks daily |
| Self-management | BE FAST and calling 911 | Every visit | Completed today | Reviewed |
| Self-management | Culturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic care | Every visit | Completed today | Lomilomi continues by her choice; her ʻohana is involved as she wishes |

## Goal progress

- No recurrent stroke or transient ischemic attack. In progress; target 2026-08-24. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-20: 132 to 64 mg/dL on atorvastatin 40 mg. **S**
- Blood pressure below 130/80 mmHg at home and in the clinic. Outcome by 2026-06-15: 126/74 in the clinic; home average 124/72. **S**
- Anticoagulation that is safe and taken as prescribed, without major bleeding. In progress; target 2026-08-24. **S**
- Keep playing the piano and composing. Outcome by 2026-06-15: Playing daily; modified Rankin Scale 1 at three months. **S**

## Guideline basis

- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021), American Heart Association and American Stroke Association (Stroke 2021;52(7):e364-e467)
- Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021), American Heart Association and American Stroke Association (Stroke 2021;52(9):e558-e571)
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023), American College of Cardiology, American Heart Association, American College of Chest Physicians and Heart Rhythm Society (Circulation 2024;149(1):e1-e156)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026), Aether Forge
- Signs and Symptoms of Stroke (2026), Centers for Disease Control and Prevention
- Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026), Ke Ola Mamo
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force

## Follow-up

- Annual wellness visit in four weeks. Five-month review in ten weeks with a lipid panel, blood count, kidney function and the MoCA. Call 911 for any BE FAST sign. **S**
- Next scheduled visit 2026-07-13: subsequent annual wellness visit. **S**
